STAT3/NF‐κB signalling disruption in M2 tumour‐associated macrophages is a major target of PLGA nanocarriers/PD‐L1 antibody immunomodulatory therapy in breast cancer

This is a publication. If there is no link to the publication on this page, you can try the pre-formated search via the search engines listed on this page.

Authors: Rômulo S. Cavalcante, Uta Ishikawa, Emanuell S. Silva, Arnóbio A. Silva‐Júnior, Aurigena A. Araújo, Luis J. Cruz, Alan B. Chan, Raimundo F. Araújo Júnior

Journal title: British Journal of Pharmacology

Journal publisher: Wiley-Blackwell

Published year: 2021

DOI identifier: 10.1111/bph.15373

ISSN: 0007-1188